Services include cloning of hybridoma sequences and production of chimeric antibodies, reformatting to antibody fragments (scFv or Fab) or from fragments to whole antibodies and production of bispecific antibodies and antibody fusion proteins. Engineering of the antibody constant region to manipulate effector function and enhance antibody stability is also accessible. Facilities can provide advice on potential strategies for therapeutic development of “non-human” antibodies for further use.
Antibody discovery services, utilising an in-house naïve human phage display scFv library, are also available. The facility has a track record in isolating antibodies against a variety of therapeutic targets, including purified proteins, cell surface antigens and peptides. Once scFv fragments are isolated, these can be engineered into whole antibodies of various isotypes.
